Linezolid versus vancomycin for MRSA skin and soft tissue infections (systematic review and meta-analysis)

ANZ Journal of Surgery

Volumn 79, Issue 9, 2009, Pages 629-635

  Dodds, Tristan John ^a,b   Hawke, Catherine Isobel ^b  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Oxazolidinones; Skin disease infectious; Soft tissue infection; Staphylococcal infection; Vancomycin

Indexed keywords

CEFAZOLIN; LINEZOLID; VANCOMYCIN;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG SAFETY; DRUG TOLERABILITY; HOSPITALIZATION; HUMAN; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; OUTCOME ASSESSMENT; SENSITIVITY ANALYSIS; SKIN INFECTION; SOFT TISSUE INFECTION; SYSTEMATIC REVIEW; TREATMENT DURATION;

ACETAMIDES; ANTI-INFECTIVE AGENTS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OXAZOLIDINONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; VANCOMYCIN;

EID: 69949095907     PISSN: 14451433     EISSN: 14452197     Source Type: Journal    
DOI: 10.1111/j.1445-2197.2009.05018.x     Document Type: Article

References (24)

1. McDonald M. The epidemiology of methicillin-resistant Staphylococcus aureus: surgical relevance 20 years on. Aust. N. Z. J. Surg. 1997 67 : 682 685.
2. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of microbiology laboratory. Clin. Microbiol. Rev. 1993 6 : 428 442.
3. Bell JM, Turnidge JD. High prevalence of oxacillin-resistant Staphylococcus aureus isolates from hospitalized patients in Asia-Pacific and South Africa: results from SENTRY Antimicrobial Surveillance Program, 1998-1999. Antimicrob. Agents Chemother. 2002 46 : 879 881.
4. Turnidge J, McCarthy LR, Master RN, Kepner DE, Weslock J. TSN Database Australia, a new tool to monitor antimicrobial resistance in Australia. Commun. Dis. Intell. 2003 27 (Suppl S67 9.
5. Whitby M, McLaws ML, Berry G. Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis. Med. J. Aust. 2001 175 : 264 267.
6. Hiramatsu K. Molecular evolution of MRSA. Microbiol. Immunol. 1995 39 : 531 543.
7. Johnson PD, Howden BP, Bennett CM. Staphylococcus aureus: a guide for the perplexed. The differences between community-acquired and health care-associated MRSA explained. Med. J. Aust. 2006 184 : 374 375.
8. Farber BF MRJ. Retrospective study of the toxicity of preperations of vancomycin from 1974 to 1981. Antimicrob. Agents Chemother. 1983 23 : 138 141.
9. Moellering RC. Linezolid: the first oxazolidinone antimicrobial see comment][summary for patients in Ann. Intern. Med. 2003 Jan 21;138(2):I44; PMID: 12529109 Ann. Intern. Med. 2003 138 : 135 142.
10. Gerson SL, Kaplan SL, Bruss JB et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob. Agents Chemother. 2002 46 : 2723 2726.
11. Donohoo E. MIMS Australia Online. 2007. Available from URL: http://www.mims.com.au [Cited 11 August 2009 PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 2006 12 (Suppl 1 16 23.
12. McCollum M, Rhew DC, Parodi S. Cost analysis of switching from i.v. vancomycin to p.o. linezolid for the management of methicillin-resistant Staphylococcus species. Clin. Ther. 2003 25 : 3173 3189.
13. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 updated May 2005]. In : The Cochrane Library, Issue 3, 2005. Chichester : John Wiley & Sons, Ltd 2005.
14. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUORUM statement. Quality of reporting of meta-analyses. Lancet 1999 354 : 1896 1900.
15. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. Br. Med. J. 1994 309 : 1286 1291.
16. Lefebvre C MS. Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE. Fourth International Cochrane Colloquium. Adelaide, Australia 1996.
17. Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999 282 : 1054 1060.
18. Sharpe JN, Shively EH, Polk HC. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am. J. Surg. 2005 189 : 425 428.
19. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents. Chemother. 2005 49 : 2260 2266.
20. Kaplan SL, Afghani B, Lopez P et al. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr. Infect. Dis. J. 2003 22 (9 Suppl S178 85.
21. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 2002 34 : 1481 1490.
22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin. Trials 1986 7 : 177 188.
23. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995 273 : 408 412.
24. Dickersin K. How important is publication bias? A synthesis of available data. AIDS Educ. Prev. 1997 9 (Suppl. A 15 21.